Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunohistochemistry analysis of formalin-fixed paraffin-embedded human small intestine stained using a Latexin polyclonal antibody (Product # PA5-23253) at 5 ug/ml. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.
|Tested species reactivity||Bovine, Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide (202 HPQYGTKVKHNSRLPKEV 219) of Latexin protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:1000|
|Immunohistochemistry (Paraffin) (IHC (P))||5 µg/ml|
|Western Blot (WB)||0.01-0.1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Latexin, the only endogenous specific inhibitor known for zinc-dependent metallocarboxypeptidases, is a 222 amino acid protein belonging to the protease inhibitor I47 (latexin) family. Human latexin is an elongated molecule with N- and C-terminal domains that each consist of an alpha helix enveloped by a curved beta sheet and the two domains are separated by a connecting segment. Latexin is a hardly reversible, non-competitive, and potent inhibitor of CPA1, CPA2 and CPA4 but is less potent against other mammalian carboxypeptidases, and it does not inhibit enzymes of other carboxypeptidase classes like metallopeptidases or serine proteases. In rat, Latexin may be used as a molecular marker for the regional specification of the neocortex. It is expressed in most tissues with high expression in brain, lung and digestive tract.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
ECI; endogenous carboxypeptidase inhibitor; latexin; MUM; TCI; tissue carboxypeptidase inhibitor
BOS_1148; ECI; LXN; TCI